{"id":"p-o-moxypen-500-mgx3-d-for-5-days","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Diarrhea"},{"rate":"3-5","effect":"Nausea"},{"rate":"1-3","effect":"Rash"},{"rate":"0.1-1","effect":"Allergic reaction / anaphylaxis"},{"rate":"2-4","effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Amoxicillin is a beta-lactam antibiotic that penetrates bacterial cell walls and irreversibly binds to penicillin-binding proteins, inhibiting the cross-linking of peptidoglycan strands. This disrupts cell wall integrity, leading to bacterial cell lysis and death. It is bactericidal and effective against a broad spectrum of gram-positive and some gram-negative bacteria.","oneSentence":"Moxypen (amoxicillin) inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins and preventing peptidoglycan cross-linking.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:59:29.784Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial infections (respiratory tract infections, otitis media, sinusitis, urinary tract infections, skin and soft tissue infections)"},{"name":"Helicobacter pylori eradication (as part of combination therapy)"}]},"trialDetails":[{"nctId":"NCT02819570","phase":"PHASE4","title":"Comparison of Two Antibiotic Prophylactic Protocols in Preterm Premature Rupture of the Membranes","status":"UNKNOWN","sponsor":"Western Galilee Hospital-Nahariya","startDate":"2015-11","conditions":"Premature Rupture of Membrane","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"P.O moxypen 500 mgx3/d for 5 days","genericName":"P.O moxypen 500 mgx3/d for 5 days","companyName":"Western Galilee Hospital-Nahariya","companyId":"western-galilee-hospital-nahariya","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Moxypen (amoxicillin) inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins and preventing peptidoglycan cross-linking. Used for Bacterial infections (respiratory tract, urinary tract, skin and soft tissue, otitis media, sinusitis), Helicobacter pylori eradication (as part of combination therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}